EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies

Sonja Ständer iD, Sarina B Elmariah, Shawn G Kwatra, Gil Yosipovitch, Andrew E Pink, Soo Yeon Cheong, Xiaoxiao Chen, Zarif K Jabbar-Lopez, Liliana Ulianov, Christophe Piketty iD, Jonathan I Silverberg iD

Journal of the European Academy of Dermatology and Venereology · 2026

DOI: 10.1111/jdv.70250 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2026. Verfasst von Sonja Ständer und 10 weiteren Autor:innen. Beteiligte Einrichtung: Section Pruritus Medicine, Department of Dermatology and Center for Chronic Pruritus, University Hospital Münster, Münster, Germany. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Pruritus, Prurigo, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Galderma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives Itch is the most burdensome symptom in atopic dermatitis (AD) and prurigo nodularis (PN) and is associated with significant psychological distress, sleep deprivation and impaired quality of life. Achieving rapid control of itch is expected to minimize symptomatology and disease burden. Nemolizumab, which targets the interleukin 31 (IL‐31) pathway, rapidly relieved itch in Phase 2 trials; thus, a post hoc analysis of four pivotal randomized controlled clinical trials of nemolizumab in AD and PN was performed to further evaluate the improvement of itch over the first 14 days of therapy.

Methods

Data from ARCADIA 1 and 2 in AD ( N = 1728) and OLYMPIA 1 and 2 in PN ( N = 560) were analysed. Patients reported itch intensity and sleep disturbance daily. Differences in the proportion of itch and sleep responders (patients with ≥4‐point improvement from baseline in peak pruritus numerical rating scale [PP‐NRS] or sleep disturbance [SD‐NRS] score) between nemolizumab and placebo groups were calculated.

Results

Nemolizumab rapidly reduced itch in AD (ARCADIA 1 and 2), with a difference versus placebo in PP‐NRS responders apparent by Day 2 (pooled data: 10.7% vs. 2.9%; 95% CI: 5.6–10.1; p < 0.0001) that steadily increased through Day 14. Nemolizumab also reduced itch rapidly in PN (OLYMPIA 1 and 2); a difference versus placebo occurred by Day 2 (pooled data: 17.2% vs. 3.7%; 95% CI: 6.8–16.7; p < 0.0001). Early improvement (Day 2) was also observed in sleep in nemolizumab‐treated patients. In pooled analyses in AD, 9.9% (nemolizumab) versus 4.6% (placebo; 95% CI: 2.8–7.7; p = 0.0001) were SD‐NRS responders and in PN, 13.4% versus 4.3% (95% CI: 4.0–13.0; p = 0.0013). Itch and sleep response data in individual studies were consistent with the pooled data.

Conclusions

This analysis confirms previously reported data that nemolizumab relieves itch and sleep disturbance by Day 2 in patients with moderate‐to‐severe AD and PN, indicating that targeting the IL‐31 pathway presents an important way to achieve rapid itch response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicPruritusPrurigoAntibodies, Monoclonal, HumanizedHumansMaleAdultFemaleMiddle AgedYoung AdultAdolescent

Stichwörter der Autor:innen

atopic dermatitiseczematous diseaseinterleukin 31itchnemolizumabonset of actionprurigo nodularispruritussleep disturbance

Substanzen

Antibodies, Monoclonal, Humanizednemolizumab

Autor:innen und Institutionen

  • Section Pruritus Medicine, Department of Dermatology and Center for Chronic Pruritus, University Hospital Münster, Münster, Germany.
  • University of California San Francisco Center for Itch and Neurosensory Disorders, San Francisco, California, USA.
  • Department of Dermatology, University of Maryland School of Medicine, Baltimore, Maryland, USA.
  • Dr Philip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, Miami Itch Center, University of Miami, Miami, Florida, USA.
  • St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.
  • Galderma Laboratories, LP, Dallas, Texas, USA.

ORCID-Profile: Sonja Ständer, Christophe Piketty, Jonathan I Silverberg

Förderung

  • Galderma

Zitieren

APA

Ständer, S., Elmariah, S. B., Kwatra, S. G., Yosipovitch, G., Pink, A. E., Cheong, S. Y., Chen, X., Jabbar-Lopez, Z. K., Ulianov, L., Piketty, C., & Silverberg, J. I. (2026). Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.70250

Vancouver

Ständer S, Elmariah SB, Kwatra SG, Yosipovitch G, Pink AE, Cheong SY, et al. Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies. Journal of the European Academy of Dermatology and Venereology. 2026. doi:10.1111/jdv.70250

BibTeX
@article{Stnder2026,
  author = {Ständer, Sonja and Elmariah, Sarina B and Kwatra, Shawn G and Yosipovitch, Gil and Pink, Andrew E and Cheong, Soo Yeon and Chen, Xiaoxiao and Jabbar-Lopez, Zarif K and Ulianov, Liliana and Piketty, Christophe and Silverberg, Jonathan I},
  title = {Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2026},
  doi = {10.1111/jdv.70250}
}
Kostenlos starten →